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Highlights of the study 
 
We evaluated the relationship of RLS and mortality in chronic hemodialysis patients  
 
For the diagnosis of RLS we implemented standard methodology, i.e. the essential 
clinical criteria of the International RLS Study Group.   
 
This is the first time this issue is investigated in an epidemiological survey in Greece.  
 
In contrast to previous reports the diagnosis of RLS does not influence the 3-year 
mortality in HD patients.  
 
ABSTRACT 
Objective: In chronic hemodialysis (HD) patients, the prevalence of restless legs 
syndrome (RLS) is significantly higher than in the general population. Uremic RLS 
has been related to an enhanced mortality of HD patients. In the general population, 
however, studies of this association have yielded inconsistent results. The aim of the 
present study was to re-evaluate the relationship of RLS and mortality in HD patients.  
Methods: We recorded the 3-year mortality rate in a population of 579 HD patients 
after assessment for RLS symptoms. In addition we analyzed the 5-year mortality rate 
after end-stage renal disease onset (i.e., commencement of HD). This HD patient 
population has been previously included in a cross-sectional survey of RLS 
prevalence in which RLS diagnosis was based on the essential clinical criteria of the 
International RLS Study Group. Mortality data were acquired from the national end-
stage renal disease registry. Survival probability was calculated by means of the 
Kaplan–Meier method and analyzed by the log-rank (Mantel–Cox) test. For 
multivariate survival analysis, we implemented a proportional hazards regression 
(Cox regression) model. 
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Results: During the 3-year follow-up period, we documented 118 deaths and an 
overall 3-year mortality of 20.6%. Mortality was 15.6% in patients with RLS and 
22.3% in patients without RLS (p = 0.079). According to the Cox regression analysis, 
there was no significant association between RLS and 3-year mortality, either in an 
age- and gender-adjusted model (hazard ratio [HR] = 0.772, 95% confidence interval 
[CI] = 0.488–1.219, p = 0.267) or in a multivariate adjusted model (HR = 0.667, 95% 
CI = 0.417–1.069, p = 0.092). Similarly, there was no association between RLS and 
5-year mortality after end-stage onset based on our univariate (HR = 0.653, 95% CI = 
0.417–1.022, p = 0.063) and multivariate (HR = 0.644, 95% CI = 0.399–1.0380, p = 
0.071) analyses.  
Conclusion: Diagnosis of RLS according to the essential clinical criteria of the 
International RLS Study Group does not seem to influence the 3-year mortality in HD 
patients. Our findings are in contrast to those in some previous reports, and reinforce 
the need for further studies of RLS and mortality in HD patients. 
 
Page 4 of 35
 5 
1. Introduction 
Restless legs syndrome (RLS), or Willis–Ekbom disease, is a neurological, 
sensorimotor disorder that frequently leads to sleep disturbances. It is characterized by 
an urgent, uncontrolled need to move the limbs that is accompanied or caused by 
peculiar, unpleasant sensations (paresthesiae). Symptoms appear or worsen at rest, are 
temporarily relieved by movement of the affected extremities, and are more severe in 
the evening or at night [1–3]. 
RLS is typically an idiopathic disorder (i.e., primary RLS); however, 
secondary forms are not infrequent. In this context, results from several cross-
sectional studies suggest an association of RLS with chronic kidney disease and 
cardiovascular diseases [4–7]. Secondary RLS in chronic kidney disease is frequently 
called “uremic RLS” [7]. In a recent epidemiological survey, in agreement with 
previous studies [5,8 –10], we found a high prevalence of RLS in patients on chronic 
hemodialysis (HD) [11].  
Uremic RLS has been frequently associated with increased morbidity and 
enhanced mortality in patients with end-stage renal disease [12–15]. In the general 
population, however, studies of this association have reported inconsistent results. A 
prospective cohort study of the Health Professionals Follow-up Study, which included 
18,425 U.S. men free of diabetes, arthritis, and renal failure, suggested that men with 
RLS had a higher overall mortality independently of known risk factors [16]. Notably, 
when duration of symptoms was taken into account, previously healthy women with 
RLS for ≥3 years showed a higher risk of coronary heart disease than women with a 
shorter duration of symptoms [17]. In contrast, according to results from four large, 
prospective cohort surveys from Germany and the United States, RLS did not increase 
all-cause mortality [18].  
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In the present study, our aim was to evaluate the association between RLS 
status and 3-year all-cause mortality, after assessment of RLS, in a cohort of HD 
patients who were recently surveyed by our group. An additional aim was to 
investigate possible modifiers of this association, that is, parameters related to uremia, 
quality of dialysis, renal anemia, iron status, cachexia–inflammation, and bone 
metabolism, all presumed predictors of all-cause and cardiovascular mortality in HD 
patients.  
 
2. Methods 
 
We conducted an observational, prospective cohort investigation in a population of 
579 HD patients. This population consisted of all patients with end-stage renal disease 
who were receiving chronic HD treatment (≥2 times per week for at least 3 months), 
in six renal units in Greece between January and September 2010. In a previous cross-
sectional survey of our group [11], conducted by means of standard methodology 
[19–21], we assessed the prevalence and severity of RLS in this population. Briefly, 
the local version of the four essential clinical criteria of the International Restless 
Legs Syndrome Study Group (IRLSSG) rating scale, which has been validated in 
previous studies, was implemented as a screening tool for RLS diagnosis [11,20]. In 
cases that fulfilled all four criteria, diagnosis was confirmed, and RLS severity was 
evaluated according to the IRLSSG rating scale (Greek version) during a personal 
interview conducted by an RLS expert (G.M.H.) [11,19,20]. According to the 
IRLSSG rating scale, severity was classified as mild (<11 on the IRLSSG rating 
scale), moderate (11–20), severe (21–30), and very severe (31–40) [21]. The 
Page 6 of 35
 7 
prevalence of RLS found in that study was 26.6% (154/579). The study presented 
here was approved by the Ethics Review Board of the University Hospital of Larissa.  
The main outcome (primary endpoint) of the study was mortality during a 3-
year observation period (2011–2013) after the assessment for RLS at baseline. Overall 
survival time was defined as the time interval from the enrollment until the date of 
death (event) or until 36 months after enrollment. The observation time of 3 years was 
held in all cases. An additional outcome was mortality assessed during a 5-year period 
after the initiation of HD. In this case, survival time was defined as the time interval 
from commencement of the HD treatment until the date of death (event) or until 60 
months after commencement of HD. Mortality data were acquired from the national 
end-stage renal disease registry [22]. Clinical and laboratory data relevant for 
mortality that had been recorded at baseline from the medical records are shown in 
Tables 1 and 2. During the 3-year follow up period, no additional data from patients 
or patients’ records were acquired except if necessary to confirm or to clarify registry 
mortality data. To calculate the probability of error for comparison of these baseline 
characteristics among survivors and nonsurvivors, we used the χ2 test for categorical 
variables and the Student t test for continuous variables (alternatively the Mann–
Whitney U test where applicable). Kaplan–Meier survival curves were generated for 
survival probability and analyzed by the log-rank (Mantel–Cox) test. Hazard ratios 
(HR) and respective 95% confidence intervals (95% CI) were estimated by a stratified 
proportional hazards regression (Cox regression) analysis. RLS existence at study 
baseline (yes/no), RLS existence before the onset of dialysis (yes/no), and RLS 
severity (mild, moderate, severe, very severe) served as stratifying variables. The 
proportional hazards assumption was tested graphically by means of log minus log 
survival curves.  
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For multivariate survival analysis, we applied the proportional hazards 
regression (Cox regression). In the first analysis, all variables that were different 
between RLS positive and negative cases (potential determinants of RLS diagnosis) 
according to the findings of the primary cross-sectional study (Tables 1 and 2) were 
included as covariates in the Cox regression models. In the second analysis, every 
potential determinant of mortality in HD patients, among the clinical and laboratory 
data recorded at baseline (Tables 1 and 2), was included as a covariate. Outcomes 
were 3-year survival after the assessment for RLS symptoms (i.e., initiation of study) 
and 5-year survival after end-stage onset (i.e., initiation of HD). Consequently, we 
implemented the proportional hazards regression (Cox regression) in four separate 
models. The existence of RLS (yes/no) at baseline served as a categorical (stratifying) 
variable in all four models. Only cases with full data sets were used for these 
analyses.  
In the first model, in which the outcome was 3-year mortality after RLS 
assessment, the following covariates were included (Tables 1 and 2): age (years), β2-
microglobulin (mg/L), ferritin (ng/mL), phosphorus (P; mg/dL), and intact 
parathyroid hormone (iPTH) (pg/mL). In the second model (3-year mortality after 
RLS assessment), the following covariates were included: age (years), sex 
(male/female), diabetic nephropathy (yes/no), duration of dialysis (months), dialysis 
mode (HD or hemodiafiltration), body mass index (kg/m
2
), serum urea before HD 
(mg/dL), urea reduction ratio (URR; %), Kt/V, β2-microglobulin (mg/L), C-reactive 
protein (mg/L), albumin (g/dL), hemoglobin (g/dL), serum iron (μg/dL), ferritin 
(ng/mL), transferrin (mg/dL), transferrin saturation (TSAT; %), calcium (Ca; mg/dL), 
phosphorus (P; mg/dL), CaxP product (mg
2
/dL
2
), and iPTH (pg/mL).  
Comment [KVS2]: AUTHOR: Please verify that 
“iPTH” is correct as expanded. 
Comment [KVS3]: AUTHOR: Please expand 
“Kt/V” at first mention in text and in table footnotes. 
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In the additional two models, in which the outcome was the 5-year survival 
after initiation of HD, the above two sets of covariates were used, principally 
unchanged. Exceptions were the duration of dialysis (months), which being zero per 
definition was not taken into account, and the age at RLS assessment (i.e. age at study 
initiation), which was substituted with the age at end-stage onset (i.e. age at initiation 
of HD). Covariates, even if they do not have a statistical significant influence on the 
outcome, may have a considerable influence on the estimation of model parameters 
for the other covariates, especially if they are associated with each other. Therefore, 
based on the above primary multivariate analyses we calculated certain reduced forms 
of all the models, first, by omitting the covariates which were significantly correlating 
with each other and, second, by including only the covariates which were significantly 
contributing to outcome on primary analysis.  
For the purposes of the present repos, the study power calculation method 
suitable for survival analysis by the log-rank test was used prospectively [23;24]. The 
minimum number of subjects required to detect a ratio of median survival times 
(experimental group/control group) with a certain power and a two sided type I error 
probability of 5% was estimated [23,24]. A study power of 80% corresponds to a 
mean survival times ratio of 0.70 for the above given sample size of patients (154 
with RLS) and controls (425 without RLS).  
Data for continuous variables are given as a mean value and standard 
deviation (SD). Categorical variables are presented as number of cases (n) or 
percentage (%). p Values ≤ 0.05 (two-sided) were regarded as statistically significant. 
Statistical analyses were carried out using the Statistical Package for Social Sciences 
13.0 (SPSS 13.0) for Windows (SPSS Inc., Chicago, IL, USA).  
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3. Results 
 
Overall, the epidemiological survey included 579 patients (236 females; mean age 65 
± 13 years) with end-stage renal disease treated with chronic HD. Among the HD 
patients who were informed about the study, none denied participation, but 24 patients 
were not included for reasons irrelevant to the study protocol (Fig. 1). For all patients 
included in the study (N = 579), there was a full dataset. No false-positive cases were 
assessed during the interview conducted by the RLS expert (G.M.H.); that is, RLS 
was confirmed in all patients who fulfilled all four criteria.  
During the 3-year period (2011–2013), we documented 118 deaths among 579 
HD patients, that is, a 3-year all-cause mortality of 20.6% overall. Specifically, 94 
patients without RLS (94/425; 3-year mortality 22.3%) and 24 patients with RLS 
(24/154; 3-year mortality 15.6%) died. Clinical profiles and laboratory findings at 
initial assessment of patients on chronic HD are shown on Tables 1 and 2. Between 
survivors and nonsurvivors with RLS, there were no significant differences in clinical 
profiles, especially concerning the existence of RLS before the onset of HD (p = 
0.229) or the severity of RLS (p = 0.430) at initial assessment (Table 1). In contrast, 
there were significant differences regarding patient age (60 ± 13 vs 67 ± 10 years, p = 
0.041), TSAT (18.5% ± 11.7% vs 13.6% ± 7.4%, p = 0.044), serum levels of 
transferrin (186 ± 40 vs 213 ± 51 mg/dL, p = 0.013), and serum levels of C-reactive 
protein (1.0 ± 2.3 vs 2.8 ± 5.8 mg/L, p = 0.036). However, between survivors and 
nonsurvivors, there were no significant differences regarding Kt/V (1.1 ± 0.2 vs 1.1 ± 
0.3, p = 0.647), URR (64.5% ± 5.0% vs 64.5% ± 8.5%, p = 0.632), or serum levels of 
β2-microglobulin (3.5 ± 1.2 vs 5.4 ± 5.8 mg/L, p = 0.068) (Table 2). Comment [KVS4]: AUTHOR: Please note that 
“microgrobulin” has been changed to 
“microglobulin” throughout. 
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The Kaplan–Meier survival curves and the log-rank (Mantel–Cox) test values 
(p = 0.079) for the 3-year survival after assessment of RLS are shown in Fig. 2. The 
proportional hazards assumption holds. The respective univariate Cox regression 
analysis showed no significant association of mortality with the diagnosis of RLS (HR 
= 0.671, 95% CI = 0.429–1.051, p = 0.081), the existence of RLS before the onset of 
HD (HR = 0.800, 95% CI = 0.564–1.135, p = 0.211), or the severity of RLS (HR = 
0.899, 95% CI = 0.720–1.120, p = 0.346). In the same analysis, diabetic nephropathy 
as the primary disease (p = 0.039), aging (p < 0.001), and enhanced serum β2-
microglobulin (p < 0.001), C-reactive protein (p < 0.001), and calcium (p < 0.001) all 
favored mortality in HD patients, whereas increased hemoglobin (p = 0.037), serum 
iron (p = 0.004), and TSAT (p = 0.005) did not (Table 3).  
In a primary multivariate proportional hazards regression (Cox regression) 
analysis, there was no significant association between RLS and 3-year all-cause 
mortality even in the age- and sex-adjusted model (HR = 0.772, 95% CI = 0.488–
1.219, p = 0.267). After adjustment for potential determinants of RLS there was no 
significant effect of the diagnosis RLS on survival of HD patients (HR = 0.669, 95% 
CI = 0.413–1.084, p = 0.102). In this first model, only age (p = 0.001) and β2-
microglobulin (p < 0.001) were independent survival predictors. The reduced final 
model, calculated on the basis of the above findings, is shown in Table 4. Similarly, 
after adjustment for all potential determinants of mortality, there was no significant 
effect of RLS on survival (HR = 0.676, 95% CI = 0.412–1.110, p = 0.122). In this 
second model, diabetic nephropathy as primary disease (p = 0.013), age (p = 0.027), 
β2-microglobulin (p = 0.002), and C-reactive protein (p < 0.001) were the only 
independent survival predictors. The final results of the respective reduced model are 
shown in Table 3. 
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Kaplan–Meier survival curves and log-rank (Mantel Cox) test values (p = 
0.052) for the 5-year survival after initiation of HD are shown in Fig. 3. The 
proportional hazards assumption holds. The univariate Cox regression analysis of the 
5-year survival showed no significant association of mortality either with the 
diagnosis of RLS (HR = 0.653, 95% CI = 0.417–1.022, p = 0.063) or with the severity 
of RLS (HR = 0.881, 95% CI = 0.707–1.098, p = 0.260). In the same analysis, age at 
dialysis onset (p < 0.001), diabetic nephropathy as the primary disease (p = 0.001), 
HDF as dialysis modus (p = 0.023), and enhanced serum levels of β2-microglobulin (p 
< 0.001), C-reactive protein (p < 0.001), or calcium (p = 0.001) all favored mortality 
in HD patients, whereas increased levels of hemoglobin (p = 0.002), serum iron (p = 
0.007), and TSAT (p = 0.005) favored survival (Table 5).  
In the primary multivariate proportional hazards regression (Cox regression) 
analysis there was no significant effect of the diagnosis of RLS on the 5-year survival 
of HD patients after adjustment for potential determinants of RLS (HR = 0.691, 95% 
CI = 0.427–1.117, p = 0.131). The reduced model, calculated on the basis of this 
analysis, is shown in Table 4. Similarly, after adjustment for potential determinants of 
mortality, we found no significant effect of RLS on survival (HR = 0.694, 95% CI = 
0.419–1.151, p = 0.157). In this model, the age at HD onset (p = 0.003), diabetic 
nephropathy as the primary disease (p = 0.005), and enhanced serum levels of β2-
microglobulin (p = 0.022) or C-reactive protein (p = 0.003) were found to be 
independent survival predictors in HD patients. Findings from the reduced final 
model, calculated on the basis of the above results, are shown in Table 5.  
 
4. Discussion 
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The data from the current study did not confirm the hypothesis of a positive 
association between RLS and increased mortality in the HD population. Similarly, in 
contrast to previous surveys [13], in our study there was no observed association 
between mortality of HD patients and severity of RLS. 
Large epidemiological studies have revealed a positive association between 
RLS and mortality in the general population [16,17]. This outcome has been 
explained mainly by the detrimental effect of idiopathic RLS on metabolic, 
biochemical, and immunological factors, all known to directly or indirectly increase 
the risk for overall and/or cardiovascular mortality [6,16,25]. However, other recent 
studies strongly argue against the link between RLS and high overall mortality or 
cardiovascular morbidity and mortality [18,26].  
Similarly with the case of idiopathic RLS, the issue of mortality and uremic 
RLS is still controversial. Only a few studies have reported an association between the 
presence and/or severity of uremic RLS and high mortality rates [12–15]. In 
particular, increased severity of uremic RLS has been associated with an increased 
incidence of cardiovascular events as well as with a higher mortality rate in patients 
treated with HD [15] or with a kidney transplant [14]. The study by Unruh et al. 
(2004) also reported an association of severe RLS with mortality [13]. The number of 
patients analyzed was quite limited in these reports [12,15], and lack of power might 
be a plausible explanation for the conflicting findings between the present and 
previous reports of mortality in uremic RLS. Publication bias may be another reason 
for this contradiction. Survival studies, all positive, seem to be very scarce [12,13,15] 
among epidemiological surveys on RLS in HD patients [11,14,27–36]. 
According to further recent publications, various factors may be involved in 
the potentially increased mortality risk for the uremic RLS patients. It seems that the 
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common denominator of those factors is the detrimental effect of RLS on sleep, which 
in turn affects a number of physiological and psychological parameters that may be 
associated with increased mortality. Briefly, uremic RLS has been reported to be 
associated with diabetes mellitus [13], chronic inflammation, as indicated by the 
increased C-reactive protein levels [15], and sleep impairment [33,37], a factor that is 
well known to be associated with a cascade of pathological conditions that affect 
health and mortality [38].  
In our current study, the probability of survival in patients with RLS somehow 
exceeded that of HD patients free of RLS, an unexpected trend that did not reach 
statistical significance. Survivor bias induced by the cross-sectional design might be 
another causative factor for this trend. In this context, a second survival analysis 
taking into account the time from the onset of HD treatment yields mostly identical 
findings. Furthermore, confounders, namely, RLS-predisposing variables according to 
the primary cross-sectional study, were checked in a separate multivariate (adjusted) 
analysis. In this model, only aging and increased β2-microglobulin levels were 
significantly predictive of mortality. Both of these confounding factors might 
influence results, especially taking into account that, in the present study, the RLS-
positive group was approximately 5 years younger that the RLS-negative group. 
Several known mortality risk factors in CKD (i.e., albumin, Kt/V, CaxP 
product) were not significantly associated with shorter survival of HD patients with 
RLS in our study. Confounding bias might be a reason for these conterintuitive 
findings. Nevertheless, in our study, there were significant differences between 
survivors and nonsurvivors regarding other clinical and biochemical characteristics, 
which have already been reported to be associated with increased mortality. In 
particular, serum levels of C-reactive protein were found to be significantly greater in 
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the nonsurvivor group of patients. In the multivariate model, increased serum levels of 
C-reactive protein are significant predictors of mortality. Interestingly, according to 
previous studies, uremic RLS may be associated with elevated C-reactive protein 
levels [15]. Other study results, however, contradict the above findings [13].  
We recently reported that increased serum levels of β2-microglobulin may be 
associated with an increased prevalence of uremic RLS in HD patients [11]. In the 
present study, β2-microglobulin levels appeared to be significantly increased in 
nonsurvivors. In multivariate models, increased β2-microglobulin levels were 
significantly predictive of mortality. 
Diabetes mellitus, a major cause of mortality among HD patients [39], has 
been also reported to be associated with severe RLS symptoms [13]. In the current 
study, the frequency of diabetic nephropathy was higher in RLS HD patients who did 
not survive in comparison to those who did survive. Although this difference was not 
statistically significant, in the multivariate model, diabetic nephropathy as a primary 
renal disease was a significant predictor against survival. This is in contrast with 
outcomes of previous studies in which diabetes mellitus was not associated with 
survival in HD patients with RLS [12].  
Various comorbidities and, in particular, cardiovascular risk factors are 
reported to be significant independent predictors of idiopathic RLS [40]. However, 
idiopathic RLS itself has not been shown to be a risk factor for cardiovascular 
morbidity [40,41] unless perhaps when duration of RLS symptoms is taken into 
account [17]. It is well known that patients with RLS (either secondary or idiopathic) 
also experience increased leg movement activity during the night, known as periodic 
limb movements in sleep (PLMS), which is reportedly present in 80% of cases 
[42,43]. PLMS severity was reported to be associated with high mortality in patients 
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with end-stage renal disease [44]. In addition, our group has reported that HD patients 
with severe PLMS were found to exhibit significant alternations in cardiac structure 
[45], which has been also confirmed in patients with idiopathic RLS [46]. 
Interestingly, in this previous study [45], the severity of RLS, in contrast to the 
severity of PLMS, was not related to structural cardiac abnormalities. In addition, it 
has been shown that RLS patients with severe PLMS present with significantly 
enhanced C-reactive protein levels in comparison to those with fewer PLMS [47]. In 
the current study, we did not assess PLMS, which is common in studies of uremic 
RLS, as it is difficult to persuade HD patients to undergo a full polysomnography for 
the purposes of an epidemiological study. Moreover, in the current study, the severity 
of RLS, assessed by the IRLSSG rating scale, was not associated with all-cause 
mortality in HD patients. 
The main strengths of this study are the large number of patients (one of the 
highest in the literature) and the validated measures used for the initial RLS diagnosis 
(including personal interview and confirmation by an expert neurologist) [11]. 
Limitations of the current study are all those of a survival analysis with a cross-
sectional and retrospective design. Cross-sectional investigations of survival with 
prevalent case assessment may be associated with a significant survivor bias. In 
addition, the time-point of RLS onset was not assessed, although duration of RLS 
symptoms might significantly influence mortality [17]. Patient data were drawn from 
medical records kept in the different dialysis units, and mortality data were acquired 
from the national end-stage renal disease registry [22] and confirmed or clarified 
when necessary from the above medical records. No time-dependent variables were 
assessed. In the 3-year follow-up, no information was assessed about treatment of 
RLS in our patients. It is important to recognize this as another study limitation, 
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especially because participation in the primary cross-sectional study has probably 
enhanced awareness and also the treatment rate of RLS, which in turn might have 
significantly influenced survival. In this context, data about kidney transplantation 
during the 3-year follow-up time were not assessed. Taking into account these 
limitations, any conclusions about mortality based on this study must be drawn with 
great caution [48,49]. A further weakness is that we did not assess PLMS, which has 
been associated with increased cardiovascular risk in HD patients [45] and could 
prove to be a significant factor in explaining literature discrepancies regarding 
mortality or cardiovascular risk in HD patients.  
In conclusion, the existence of an RLS diagnosis according to the essential 
clinical criteria of the IRLSSG did not influence the 3-year mortality rate in HD 
patients. Likewise, there was no association between RLS and 5-year mortality after 
HD onset. Our findings are in contrast to those of some previous studies, and 
reinforce the need for further investigations regarding RLS and mortality in HD 
patients.  
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Fig. 1. Flowchart of participants in the epidemiological survey on the RLS in 
hemodialysis (HD) patients in Greece. There were 24 patients who were unable to 
participate due to inability to communicate (n = 2) or due to absence from the dialysis 
unit because of hospitalization (n = 18) or vacation (n = 6). These reasons for 
exclusion were irrelevant to the study protocol. In total, 579 HD patients gave 
informed consent and were analyzed in the epidemiological study.  
 
 
 
 
Fig. 2. Kaplan–Meier analysis of 3-year survival probability after initialization of the 
study. On comparison, performed by log-rank (Mantel–Cox) test, there was no 
significant difference (p = 0.079) of survival between hemodialysis (HD) patients 
with restless legs syndrome (RLS; n = 154) and HD patients without RLS (n = 425).  
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Fig. 3. Kaplan–Meier analysis of 5-year survival probability after commencement of 
hemodialysis (HD) treatment. On comparison, performed by log-rank (Mantel–Cox) 
test, there was no significant difference (p = 0.052) of survival between HD patients 
with restless legs syndrome (RLS; n = 154) and HD patients without RLS (n = 425).  
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Table 1 
Clinical profiles of patients with end-stage renal disease on hemodialysis (HD) treatment (N = 579). 
 
 HD patients 
 Total  RLS
–
  RLS
+
  p 
*
 RLS
+
 survived RLS
+
 died p
 *
 
 n (%) 
a
 n (%) 
b
 n (%) 
b
  N  (%) 
b
 n  (%) 
b
  
Primary kidney disease        
Diabetic nephropathy 135 (23.3) 105 (77.8) 30 (22.2)  23 (76.7) 7 (23.3)  
Vascular kidney disease 135 (23.3) 93 (68.9) 42 (31.1)  36 (85.7) 6 (14.3)  
Glomerulonephritis 102 (17.6) 71 (69.6) 31 (30.4)  28 (90.3) 3 (9.7)  
Polycystic kidney disease 37 (6.4) 26 (70.3) 11 (29.7)  8 (72.7) 3 (27.3)  
Chronic interstitial nephritis  51 (8.8) 40 (78.4) 11 (21.6)  9 (81.8) 2 (18.2)  
Systemic disease 27 (4.7) 19 (70.4) 8 (29.6)  7 (87.5) 1 (12.5)  
Other causes 76 (13.1) 58 (76.3) 18 (23.7)  16 (88.9) 2 (11.1)  
Unknown etiology 16 (2.8) 13 (81.2) 3 (18.8) 0.624 3 (100) 0 (0) 0.741 
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Sum 579 (100) 425 (73.4) 154 (26.6) N/A 130 (84.4) 24 (15.6) N/A 
Profile of HD patients with RLS  n (%)
 a
 n (%)
 a
 n (%)
 a
  n (%)
 a
 n (%)
 a
  
RLS family history
§
 6 (1.04) 1 (0.24) 5 (3.25) 0.006 5 (3.8) 0 (0) 0.329 
RLS beginning before HD 31 (5.35) N/A 31 (20.1) N/A 24 (18.5) 7 (29.2) 0.229 
Peripheral neuropathy 86 (14.8) 52 (12.2) 34 (22.1) 0.005 27 (20.8) 7 (29.2) 0.362 
Severity (IRLSSG rating scale) n  (%)
 a
 n  (%)
 a
 n  (%)
 a
  N  (%)
 a
 n  (%)
 a
  
Mild RLS (<11) 66 (11.4) N/A 66 (42.9)  59 (45.4) 7 (29.2)  
Moderate RLS (11–20) 63 (10.9) N/A 63 (40.9)  52 (40.0) 11 (45.8)  
Severe RLS (21–30) 21 (3.6) N/A 21 (13.6)  16 (12.3) 5 (20.8)  
Very severe RLS (31–40) 4 (0.7) N/A 4 (2.6) N/A 3 (4.2) 1 (4.2) 0.430 
 
Comparison between HD patients with RLS (n = 154) or without RLS (n = 425) in an initial assessment and comparison between survivors (n = 
130) or nonsurvivors (n = 24) with RLS in a 3-year survival analysis. p Values were calculated by the Mann–Whitney U test for continuous 
variables or the χ2 test for categorical variables. IRLSSG, International Restless Legs Syndrome Study Group; N/A, ; RLS, restless legs 
syndrome; RLS family history, RLS diagnosis in at least one first-degree relative (free of nephropathy) of the patient. 
a 
Percentage of column total number (n). 
b 
Percentage of row total number (n).
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Table 2 
Clinical and laboratory parameters in patients with end-stage renal disease on hemodialysis (HD) treatment (N = 579). 
 
 HD patients 
Parameter Total HD RLS

 RLS
+
 p* RLS
+
 survived RLS
+
 died p
1
 
No. of patients (n) 579 425 154 N/A 130 24 N/A 
Sex (male/female) 343/236 260/165 83/71 0.126 71/59 12/12 0.824 
Age (y) 65 ± 13 66 ± 13 61 ± 13 <0.001 60 ± 13 67 ± 10 0.041 
Time on HD (mo) 42.9 ± 44.7 
41.3 ± 
45.0 
47.4 ± 43.6 0.071 48.6 ± 44.2 40.6 ± 40.1 0.311 
Body mass index (kg/m
2
) 25.3 ± 4.1 25.3 ± 4.0 25.4 ± 4.2 0.925 25.2 ± 3.9 26.5 ± 5.2 0.388 
Mode of treatment (HDF/HD)  134/445 93/332 41/113 0.265 36/94 5/19 0.618 
Diabetic nephropathy (yes/no) 135/444 105/320 30/124 0.118 23/107 7/17 0.192 
Serum urea before HD (mg/dL) 152 ± 35 150 ± 36 155 ± 33 0.197 155 ± 34 156 ± 38 0.749 
Urea reduction ratio (%) 65.1 ± 6.2 65.3 ± 6.4 64.5 ± 5.6 0.144 64.5 ± 5.0 64.5 ± 8.5 0.632 
Kt/V 1.1 ± 10.2 1.1 ± 0.2 1.1 ± 0.2 0.343 1.1 ± 0.2 1.1 ± 0.3 0.647 
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β2-Microglobulin (mg/L) 3.4 ± 1.8 3.3 ± 1.3 3.8 ± 2.6 0.011 3.5 ± 1.2 5.4 ± 5.8 0.068 
C-reactive protein (mg/L) 1.2 ± 2.7 1.2 ± 2.5 1.3 ± 3.2 0.890 1.0 ± 2.3 2.8 ± 5.8 0.036 
Albumin (g/dL) 4.09 ± 0.36 
4.07 ± 
0.37 
4.13 ± 0.32 0.100 4.15 ± 0.32 4.05 ± 0.32 0.254 
Hemoglobin (g/dL) 11.3 ± 1.2 11.3 ± 1.2 11.2 ± 1.3 0.632 11.2 ± 1.3 11.2 ± 1.1 0.594 
Serum iron (μg/dL) 48.3 ± 27.4 
49.4 ± 
28.0 
45.2 ± 25.5 0.067 46.4 ± 26.5 38.6 ± 18.1 0.408 
Ferritin (ng/mL) 270 ± 259 275 ± 249 254 ± 286 0.035 221 ± 289 217 ± 274 0.733 
Transferrin (mg/dL) 191 ± 44 191 ± 44 190 ± 43 0.582 186 ± 40 213 ± 51 0.013 
Transferrin saturation (%) 18.9 ± 11.6 
19.3 ± 
11.7 
17.8 ± 11.3 0.109 18.5 ± 11.7 13.6 ± 7.4 0.044 
Calcium (mg/dL) 8.8 ± 0.8 8.8 ± 0.8 8.8 ± 0.8 0.390 8.7 ± 0.8 9.1 ± 1.0 0.153 
Phosphorus (mg/dL) 5.5 ± 1.7 5.4 ± 1.6 5.8 ± 1.7 0.037 5.8 ± 1.8 5.8 ± 1.2 0.585 
CaxP product (mg
2
/dL
2
) 48.8 ± 15.9 
47.9 ± 
15.3 
51.2 ± 17.1 0.072 50.9 ± 17.6 52.9 ± 14.7 0.420 
Alkaline phosphatase (U/L) 97 ± 52 96 ± 52 98 ± 50 0.757 100 ± 52 84 ± 36 0.350 
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Intact parathormone (pg/mL) 294 ± 259  272 ± 240 356 ± 298 0.001 341 ± 298 434 ± 293 0.108 
Comparison between HD patients with restless legs syndrome (RLS) (n = 154) and without RLS (n = 425) at initial assessment and between 
survivors (n = 130) and nonsurvivors with RLS (n = 24) in a 3-year survival analysis. Continuous variables are expressed as mean and standard 
deviation (mean ± SD), categorical values are expressed as frequency (n ). p Values were calculated by the Mann–Whitney U test for continuous 
variables or the χ2 test for categorical variables. HDF, hemodiafiltration. 
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Table 3 
Multivariate survival analysis by proportional hazards regression (Cox regression) model. 
 
  Proportional hazards (Cox) regression analysis for 3-year mortality 
Predictor variable   Crude HR (95% CI) p  Adjusted HR (95% CI) p 
RLS  0.671 (0.429–1.051) 0.079  0.667 (0.417–1.069) 0.092 
Age (y)  1.030 (1.014–1.047) <0.001  1.024 (1.007–1.041) 0.005 
Diabetic nephropathy   1.511 (1.021–2.236) 0.039  1.316 (1.008–1.956) 0.017 
C-reactive protein (mg/L)  1.106 (1.065–1.148) <0.001  1.102 (1.059–1.146) <0.001 
β2-Microglobulin (mg/L)  1.102 (1.048–1.158) <0.001  1.107 (1.049–1.167) <0.001 
Covariates included in the model are as follows: age (i.e., age in years at study initiation), sex 
(male/female), diabetic nephropathy (yes/no), duration of dialysis (months), dialysis mode 
(hemodiafiltration or hemodialysis), body mass index (kg/m
2
), serum urea before HD 
(mg/dL), urea reduction ratio (%), Kt/V, β2-microglobulin (mg/L), C-reactive protein (mg/L), 
albumin (g/dL), hemoglobin (g/dL), serum iron (μg/dL), ferritin (ng/mL), transferrin (mg/dL), 
transferrin saturation (%), calcium (mg/dL), phosphorus (mg/dL), CaxP product (mg
2
/dL
2
), 
and intact parathyroid hormone (pg/mL). Outcome in model was 3-year survival of 
hemodialysis patients after assessment of RLS (i.e., initiation of cross-sectional study). 
Existence of RLS served as a categorical variable, and potential determinants of mortality 
recorded in hemodialysis patients were independent variables (covariates) in the model. Only 
covariates that were significant determinants of survival in the primary multivariate analysis 
were included in reduced model shown. CI, confidence interval; HR, hazard ratio; RLS, 
restless legs syndrome.
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Table 4 
Multivariate survival analysis by two proportional hazards regression (Cox regression) 
models. 
 
  
Proportional hazards (Cox) regression analysis 
  Model for 3-year mortality
 a
  Model for 5-year mortality
 b
 
Predictor variable   Adjusted HR (95% CI) P  Adjusted HR (95% CI) p 
RLS  0.709 (0.443–1.135) 0.152  0.762 (0.476–1.220)  0.258 
Age (y) 
c
  1.028 (1.011–1.045) 0.001  1.037 (1.020–1.054) <0.001 
β2-Microglobulin (mg/L)  1.113 (1.058–1.171) <0.001  1.115 (1.054–1.181) <0.001 
Only the covariates that were significant determinants of survival in the primary multivariate 
analysis were included in the finally applied reduced models shown. Outcome in the first 
model was the 3-year survival of hemodialysis patients after assessment for RLS symptoms 
(i.e., initiation of the primary cross-sectional study); outcome in the second model 5-year 
survival after end-stage onset (i.e., initiation of hemodialysis). Existence of RLS served as a 
categorical variable and potential determinants of the diagnosis RLS recorded in hemodialysis 
patients were the independent variables (covariates) in the model. CI, confidence interval; 
HR, hazard ratio; RLS, restless legs syndrome. 
a 
Covariates in first model (for 3-year mortality): age (i.e., age in years at study initiation), β2-
microglobulin (mg/L), ferritin (ng/mL), phosphorus (mg/dL), and intact parathyroid hormone 
(pg/mL).  
b 
Covariates in second model (for 5-year mortality): age at end-stage onset (i.e., age in years at 
initiation of hemodialysis), β2-microglobulin (mg/L), ferritin (ng/mL), phosphorus (mg/dL), 
and intact parathyroid hormone (pg/mL). 
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c 
Age (y) represents the age at RLS assessment (i.e., age in years at study initiation) in the first 
model (for 3-year mortality) and the age at end-stage onset (i.e., age in years at initiation of 
hemodialysis) in the second model (for 3-year mortality), respectively. 
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Table 5 
Multivariate survival analysis by a proportional hazards regression (Cox regression) model.  
 
  
Proportional hazards (Cox) regression analysis for 5-year mortality 
Predictor variable   Crude HR (95% CI) p  Adjusted HR (95% CI) p 
RLS  0.653 (0.417–1.022) 0.063  0.644 (0.399–1.0380) 0.071 
Age (y)  1.039 (1.022–1.055) <0.001  1.021 (1.005–1.038) 0.012 
Diabetic nephropathy   1.938 (1.306–2.875) 0.001  1.693 (1.131–2.535) 0.010 
C-reactive protein (mg/L)  1.080 (1.041–1.121) <0.001  1.080 (1.037–1.125) <0.001 
β2-Microglobulin (mg/L)  1.109 (1.048–1.173) <0.001  1.106 (1.042–1.174) 0.001 
Only the covariates that were significant determinants of survival in the primary multivariate 
analysis were included in the reduced model shown. Covariates included in the model were as 
follows: age (in years, at initiation of hemodialysis), sex (male/female), diabetic nephropathy 
(yes/no), dialysis mode (hemodiafiltration or hemodialysis), body mass index (kg/m
2
), serum 
urea before hemodialysis (mg/dL), urea reduction ratio (%), Kt/V, β2-microglobulin (mg/L), 
C-reactive protein (mg/L), albumin (g/dL), hemoglobin (g/dL), serum iron (μg/dL), ferritin 
(ng/mL), transferrin (mg/dL), transferrin saturation (%), calcium (mg/dL), phosphorus 
(mg/dL), CaxP product (mg
2
/dL
2
), and intact parathyroid hormone (pg/mL). Outcome in the 
model was the 5-year survival of hemodialysis patients after disease onset (i.e., initiation of 
hemodialysis). Existence of RLS served as a categorical variable and potential determinants 
of mortality recorded in hemodialysis patients were the independent variables (covariates) in 
the model. CI, confidence interval; HR, hazard ratio; RLS, restless legs syndrome. 
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